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Neuronal SNAREs and their key regulators together drive synaptic vesicle exocytosis and synaptic transmis-
sion as a single integratedmembrane fusionmachine. Human pathogenicmutations have now been reported
for all eight core components, but patients are diagnosed with very different neurodevelopmental syn-
dromes. We propose to unify these syndromes, based on etiology and mechanism, as ‘‘SNAREopathies.’’
Here, we review the strikingly diverse clinical phenomenology and disease severity and the also remarkably
diverse genetic mechanisms. We argue that disease severity generally scales with functional redundancy
and, conversely, that the large effect of mutations in some SNARE genes is the price paid for extensive inte-
gration and exceptional specialization. Finally, we discuss how subtle differences in components being rate
limiting in different types of neurons helps to explain the main symptoms.Twenty-five years after their discovery (Schiavo et al., 1995; Söll-
ner et al., 1993), the evidence of a crucial role of SNARE (soluble
NSF attachment protein receptor) complexes in many mem-
brane fusion processes in the brain is overwhelming (S€udhof
and Rothman, 2009). The neuronal SNAREs syntaxin 1,
SNAP25, and synaptobrevin/VAMP2 are at the core of a highly
conserved, integrated molecular machine that drives synaptic
transmission by synaptic vesicle exocytosis (S€udhof and Roth-
man, 2009) and also secretion of neuropeptides and neurotro-
phins from dense core vesicles (Arora et al., 2017; Shimojo
et al., 2015). Strikingly, there is no backup plan for these fusion
reactions. Inactivation of single SNARE genes or the SNARE
organizer MUNC18-1 abolishes synaptic transmission and
even prevents spontaneous fusion events in most neurons stud-
ied so far (Schoch et al., 2001; Verhage et al., 2000; Washbourne
et al., 2002). Given this lack of redundancy, mutations in the hu-
man genes encoding these proteins are expected to result in
clinically important effects on brain function. In 2008, the first hu-
man patients were described, initially with mutations in STXBP1
(Saitsu et al., 2008), the human gene encoding MUNC18-1. To
date, patients have been described carrying mutations in each
neuronal SNARE gene and in five genes encoding important or-
ganizers of neuronal SNARE function that together constitute the
integrated molecular fusion machine (Figure 1; Table 1). Most re-
portedmutations are heterozygous de novomissense or loss-of-
function (LoF) mutations (mutations that result in reduced or
abolished protein function: [partial] gene deletions, small inser-
tions, truncations, and frameshift or splice-site mutations). The
causality of these mutations is now fairly well established, at
least in a few of these genes. It could be expected that mutations
in any component of this integrated machine lead to similar
symptoms. However, recent studies now suggest that mutations
give rise to a surprisingly diverse palette of symptoms, with neu-
rodevelopmental delay (NDD) in the domains of speech, lan-22 Neuron 107, July 8, 2020 ª 2020 Elsevier Inc.guage, motor function, and intellectual ability, as the most com-
mon aspect. In addition, other neurological features associated
with severe developmental delay are observed, such as seizures
and epileptiform abnormalities, and neurological motor prob-
lems, such as spasms and ataxia (Figure 2; Table 1). Children
carrying mutations in a single SNAREopathy gene can
have more than 10 different diagnoses, depending on how
they entered the health care system (https://stxbp1.cncr.nl/
stxbp1_disorders), a situation referred to as ‘‘the diagnostic od-
yssey’’ for the families and caretakers. Hence, despite strong ev-
idence that these proteins work together in a well-integratedmo-
lecular machine, mutations in individual components produce a
surprisingly diverse collection of symptoms and diverse di-
agnoses.
The diversity of symptoms among cases and also differences
in severity resembles the clinical picture observed for carriers of
mutations in another class of functionally related proteins: the
voltage-gated K+, Na+, and Ca2+ channels, together referred to
as ‘‘channelopathies’’ (Kullmann, 2010). We propose to consider
disorders emerging from mutations in the functionally related
SNARE machinery ‘‘SNAREopathies’’—a subset of the previ-
ously defined synaptopathies (Grant, 2012). However, the latter
comprise a much more diverse group of genes; e.g., localized
to different compartments (pre- and postsynaptic) and with
diverse molecular functions. We define a SNAREopathy as a
brain disease caused by mutations that disturb synaptic SNARE
function; i.e., including disturbed functions of key regulators of
SNARE function (Table 1; together referred to as ‘‘SNAREopathy
genes’’; Figure 1). Such a functional classification provides key
advantages to (1) delineate a clinical subgroup with a common
pathogenic starting point, (2) end the diagnostic odyssey for pa-
tient families, (3) contribute to elucidation of pathogenic path-
ways toward clinical neurodevelopmental phenotypes, and (4)
eventually develop intervention strategies. The aim of this review
Figure 1. Schematic Representation of the Eight SNAREopathy Genes with Their Orientation Relative to the Synaptic Vesicle (Gray Circle)
and the Plasma Membrane (Gray Line), Their Main Protein Domains, and Their Main Interactions
SNARE domains are depicted as aligned ellipses in the center. Indicated names are commonly used protein names followed by the official gene names separated
by a comma. Firm evidence that mutations in a given gene specifically disturb synaptic SNARE function was taken as the main inclusion criterion for SNARE-
opathy genes. Hence, although only three of these eight SNAREopathy genes are SNAREs, all of them together serve a single purpose (SNARE-mediated
membrane fusion), and mutations in any of these eight are expected to lead to a single convergent defect (dysregulation of SNARE-mediated membrane fusion).
For additional genes (e.g., CSP, CAPS1/2, and STXBP5/5L [tomosyns]) and paralogs of the eight depicted genes (e.g., VAMP1, SYT2, and UNC13B), such
evidence is already accumulating, and the collection of SNAREopathy genes is likely to expand in the future. Mutations in different paralogs may also affect
neuronal or synaptic function in different populations of neurons; e.g., UNC13A for excitatory synapses (Augustin et al., 1999). Genes that regulate neuronal
SNARE function as part of a generic role in multiple cellular trafficking routes or signal transduction cascades have been excluded; e.g., aSNAP/NSF and kinases
and phosphatases.
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Reviewis to define SNAREopathies, chart the landscape of resultant
neurodevelopmental conditions with its complexity in symptoms
and disease mechanisms, and suggest explanations for this di-
versity by considering partial redundancies and a heterogeneous
effect among different neurons in the brain. Investigating these
suggestions will improve connections between disturbedmolec-
ular function of the synaptic secretion machinery and the highly
diverse clinical symptomatology and ultimately define outcome
measures to evaluate future treatments.
Molecular Functions: SNAREopathy Genes Operate as a
Highly Integrated Fusion Machine
SNARE complexes are dedicated membrane fusion machines,
and different SNARE complexes participate in membrane fusion
throughout the eukaryotic cell (Jahn and Scheller, 2006). In the
presynapse, the neuronal SNARE complex is under control of
additional proteins, some of which regulate SNARE complex as-
sembly (MUNC18 and MUNC13), whereas others also regulate
exocytosis downstream of SNARE complex formation (complex-
ins and synaptotagmins). Functional studies have shown that
formation of the SNARE complex drives vesicle ‘‘priming,’’ the
process that makes vesicles ready to be released, indicating
that primed vesicles have already formed SNARE complexes
(Walter et al., 2010). Downstream events triggered by Ca2+ and
driven by synaptotagmins and complexins precipitates struc-
tural changes in the fusion machinery that trigger synaptic
vesicle fusion and neurotransmitter release. Recent studies indi-
cate that the initial step in formation of the SNARE complex con-sists of MUNC18-1 bound to syntaxin-1 in a closed configuration
in which the SNAREmotif formation is buried and unavailable for
SNARE complex formation (Misura et al., 2000; Rizo and S€udhof,
2012; Toonen and Verhage, 2007). Although, in this configura-
tion, the SNARE motif is occluded, it forms the starting point
for SNARE complex assembly (Ma et al., 2013; Schollmeier
et al., 2011). MUNC13-1 disinhibits this autoinhibitory syntaxin:
MUNC18-1 complex and enables interactions with VAMP2 (Par-
isotto et al., 2014; Sitarska et al., 2017). The subsequent SNARE
complex formation takes place on the surface of MUNC18-1,
which acts as a template. In addition, MUNC18-1 and
MUNC13 prevent trans-SNARE complex disassembly, which
would lead to ‘‘unpriming’’—loss of primed vesicles (He et al.,
2017). RIM proteins activate MUNC13 by preventing its autoinhi-
bitory configuration and cluster Ca2+ channels with synaptic ves-
icles (Deng et al., 2011; Kaeser et al., 2011). Synaptotagmin-1
binds to the SNARE complex but might also participate in
SNARE complex assembly, vesicle docking, and priming (Bhalla
et al., 2006; Chang et al., 2018; de Wit et al., 2009; Schupp et al.,
2016). Complexins bind to and stabilize the assembled SNARE
complex and further stimulate fast synaptotagmin-driven mem-
brane fusion (Cai et al., 2008; Reim et al., 2001). Synaptotagmins
also inhibit spontaneous fusion (Courtney et al., 2019; Geppert
et al., 1994), which is necessary to protect primed vesicles
from premature fusion and build up a standing pool of primed
vesicles (RRP, readily releasable pool of vesicles); a similar func-
tion is attributed to subdomains of complexins (Lai et al., 2014; Li
et al., 2011; Makke et al., 2018; Maximov et al., 2009; Xue et al.,Neuron 107, July 8, 2020 23
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– 0–1 STX1A is often hemizygously deleted in Williams syndrome. STX1A expression correlates positively with intelligence within
the syndrome. A homozygous splice-site mutation has been found in a patient with severe ID and muscular hypotonia.
The consequence at the protein level is unknown.
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Shown is a summary of the main clinical features of SNAREopathies. ASD, autism spectrum disorder; ADHD, attention deficit hyperactivity disorder; D, Drosophila; C, C. elegans.
aProbably underdiagnosed; diagnosis incidence may depend on how the patient families entered the healthcare system.


























Figure 2. Prevalence of Symptoms for
Mutations in Different SNAREopathy Genes
The thickness of the lines indicates the prevalence
of reported symptoms and the size of the circles the
number of reported cases to date. See Table 1 for
details and references. The prevalence may be
biased by how the patient families entered the
health care system (e.g., likeliness that genetic
testing is performed and that SNAREopathy genes
are included in test panels).
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Review2007), although this function is not observed in all cell types
(Chang et al., 2015; Lopez-Murcia et al., 2019). Upon arrival of
an action potential and Ca2+ binding, synaptotagmin acts as a
switch to overcome the electrostatic energy barrier for fusion
(Chang et al., 2018; Huson et al., 2019; Martens et al., 2007;
Ruiter et al., 2019).
As part of the optimization of the fusion machine for speed, its
components have become highly integrated, as demonstrated in
elegant structural studies (Zhou et al., 2015, 2017). Hence, mu-26 Neuron 107, July 8, 2020tations in the genes encoding components
of this highly integrated molecular ma-
chine are expected to lead to changes in
the operation of the machine as a whole,
and mutations in different components to
lead to similar changes at the cellular level
and, ultimately, to similar clinical manifes-
tations.
Clinical Profiles: One Molecular
Machine, Diverse Symptoms
In spite of this prediction, mutations in
SNAREopathy genes lead to a strikingly
diverse palette of early symptoms, often
starting in the first year of life. A degree
of pervasive NDD across language, cogni-
tive, and motor milestones is the most
common aspect, often accompanied by
seizures, autistic features, spasms, ataxia,
hypotonia, hyperkinesia, or stereotypies.
For RIMS1 and SYT1, characteristic
ophthalmic abnormalities are reported
(Table 1; Figure 2): for RIMS1 mutations,
primary photoreceptor defects (cone-rod
dystrophy), whereas for SYT1 mutations,
eye positioning and movement are
affected (strabismus and nystagmus).
In terms of prevalence, most cases are
reported for MUNC18-1/STXBP1, more
than 250; around 50 for STX1B; approxi-
mately 10 for SYT1 and RIMS1 (most are
in the same family); a few for SNAP25,
VAMP2, and complexin 1 (CPLX1); and
two for UNC13A (Table 1; Figure 2). This
prevalence is expected to increase rapidly
because of increasing genetic testing
worldwide, especially when these genes
are added to the standard screeningpanels in neurodevelopmental clinical programs or when whole-
exome sequencing ismore generally introduced. Assembly of co-
horts and systematic assessment of developmental trajectories
and symptomatology has been complicated until now by the
fact that patients enter the health care system via different routes
in different countries (via pediatrics, clinical genetics, child
neurology, or child psychiatry) and by the fact that the initial diag-
noses are diverse. For instance, STXBP1 mutations, first
described in a patient diagnosedwithOhtahara syndrome (Saitsu
ll
Reviewet al., 2008), were subsequently identified as causal in patients
diagnosed with West syndrome, Dravet syndrome, Lennox-Gas-
taut syndrome, non-syndromic epilepsy, autism, and Rett-like
syndrome (see https://stxbp1.cncr.nl/stxbp1_disorders and
Stamberger et al., 2016, for further details). At present, treatment
options are generally poor and limited to non-specific symptom-
atic treatments; e.g., seizure control. A more mechanistic under-
standing of the pathogenesis, especially when shared principles
exist among mutations in different SNAREopathy genes, would
be a major step toward rational therapy design.
Although the clinical picture for most cases is severe, in a few
cases, symptoms are milder. For instance, mutations in STX1B
often cause comparatively mild developmental delay, mild ID (in-
tellectual disability), and febrile seizures. ForCPLX1, all identified
cases are homozygous children from consanguineous families
carrying missense or nonsense mutations (Table 1). These par-
ents have been described as unaffected, although more detailed
phenotyping has not yet been reported (Redler et al., 2017).
Together with the lack of ascertained patients with heterozygous
mutations, CPLX1 heterozygous mutations seem to be
nonpathogenic.
Finally, a distinct class of mutations primarily affects the pre-
synaptic part of the neuromuscular endplate, leading to congen-
ital myasthenic syndrome (Lorenzoni et al., 2018), in some cases
caused by a defect in the fusion machinery of acetylcholine ves-
icles. This machinery contains some of the same components as
the prototypic CNS fusion machinery (Figure 1; Table 1) but, in
some cases, paralogs; i.e., VAMP1 instead of VAMP2 and syn-
aptotagmin-2 instead of synaptotagmin-1. Corresponding to
this, mutations in VAMP1 and SYT2 result in ‘‘peripheral SNARE-
opathy’’ with hypotonia and areflexia and characteristic electro-
physiological features, including a reduced compound muscular
action potential that is further depressed during low-frequency
stimulation but is facilitated upon high-frequency stimulation or
voluntary contractions (Herrmann et al., 2014; Maselli et al.,
2020; Salpietro et al., 2017; Whittaker et al., 2015).
Genetic Disease Mechanisms: Diverse Mechanisms
Lead to Similar Syndromes
Most SNAREopathy cases are caused by heterozygousmissense
or LoFmutations, typicallydenovobut in rare cases inherited from
heterozygous ormosaic parents (Saitsu et al., 2011). In addition to
disease-causing mutations, recent large-scale sequencing pro-
jects (Lek et al., 2016) have revealed coding mutations in all
SNAREopathy genes in healthy individuals (so-called population
mutations). Populationmutationsmay occur in parts of the protein
where this is tolerated but also randomly throughout the gene and
even in close proximity of disease-causing mutations (https://
stxbp1.cncr.nl/stxbp1_disorders). In a few cases, mutations of
the same amino acid are found in a patient as well as in a healthy
individual (STXBP1 V84). This suggests that other factors, genetic
and/or environmental, should be considered when studying dis-
ease mechanisms.
The fact that mutations in genes that appear to have a single
common function cause such a diverse palette of symptoms is
a major challenge for understanding the underlying disease
mechanisms. On top of that, these mechanisms appear to divert
substantially among cases. Almost all SNAREopathies (exceptfor CPLX1) described to date occur in patients who carry a
normal allele and a pathogenic allele, which cannot be compen-
sated for by the normal allele (haploinsufficiency). This situation
can lead to dysfunction in several ways (Figure 3; Table 2): (1a)
LoF or missense mutations reduce protein and/or mRNA stabil-
ity, which brings the cellular level of the protein below a critical
threshold without necessarily impairing its molecular function,
or, conversely, (1b) missense mutations impair the function of
a gene without necessarily making it less stable. These two situ-
ations might be functionally similar, but therapeutic strategies
could be different (Figure 3; Table 2); e.g., stabilizing mutant pro-
teinsmay be beneficial for mutations that make proteins less sta-
ble but do not affect functionality (1a), whereas such strategies
will not work for those that do affect functionality (1b). As a further
refinement, especially for larger, multi-domain proteins (1c), mu-
tations may alter the interaction with one specific binding part-
ner, yielding a protein with an abnormal interactome and, there-
fore, a different, new balance in functionality (neomorph). In such
cases, future therapies might be specifically directed to
normalize specific downstream pathways. In addition, (2)
missense and LoF mutations can lead to dominant effects also
affecting the functionality of the protein encoded by the other
(normal) allele. In this case, therapeutic strategies might aim to
downregulate or correct the mutant protein and/or transcripts.
Finally, (3) many mutations are recessive and asymptomatic,
but rare homozygous cases cause disease. Strikingly, evidence
of all of these five scenarios has been reported for SNAREopa-
thies (Figure 3; Table 2). Hence, not only is the palette of symp-
toms diverse, but the first indications of underlying disease
mechanisms appear to be surprisingly diverse, too.
Disease-causing mutations in the three SNAREs VAMP2,
STX1B, and SNAP25 are often point mutations clustering in the
SNARE domains or in the essential Habc domain of syntaxin
1b. This pattern indicates that disruption of the (canonical)
SNARE function of these proteins probably explains the symp-
toms (scenario 1b or 1c), as demonstrated for a VAMP2
missense mutation (S75P) in an in vitro fusion assay (Salpietro
et al., 2019). Similarly, in synaptotagmin-1, five disease muta-
tions cluster in the essential Ca2+-binding C2B domain (Baker
et al., 2018). One mutation (D304G) interferes with Ca2+ binding
(scenario 1b or 1c), whereas another (M303K) affects the expres-
sion level (scenario 1a), and all mutations impair synaptic vesicle
exocytosis and recycling (Baker et al., 2018). A thorough inves-
tigation of three synaptotagmin-1 disease mutations (D304G,
D366E, and I368T) in mouse SYT1-null neurons showed that
these mutant proteins fail to support synaptic transmission on
their own, indicating profound LoF (Bradberry et al., 2020).
When co-expressed with normal protein, to emulate the hetero-
zygous condition found in patients, synaptic transmission was
restored, but titration of themutant/normal ratio revealed a domi-
nant-negative phenotype (scenario 2). The cause of the defect
was identified as impaired Ca2+-dependent lipid binding, but to
different extents in different mutants, which correlated with the
severity of the clinical phenotype (Bradberry et al., 2020). In addi-
tion, one SNAP25 mutation (I67N) has been shown to cause a
reduction in vesicle fusion when overexpressed in wild-type
mouse chromaffin cells, again indicating a dominant effect (sce-
nario 2). This mutation has been shown to interfere with releaseNeuron 107, July 8, 2020 27
Figure 3. Five Molecular Genetic Disease Mechanisms for SNAREopathies
*LoF, classical LoF mutations; i.e., (partial) gene deletions and truncations (stop codons, frameshifts, or splice-site mutations); x, see discussion in the main text.
The variation shown in this figure is restrained by lethality; i.e., more severe mutations, especially homozygous or compound heterozygous, are most likely not
compatible with life. Furthermore, different types of haploinsufficiency (1a–1c) probably occur together; e.g., if mutations impair protein stability and functionality.
Because all SNAREopathy genes have more than one established binding partner, detailed future studies will probably shift the proposed mechanisms from
‘‘functional haploinsufficient’’ (1b) to ‘‘neomorph’’ (1c) because mutations will probably affect interactions between binding partners differently, at least to some
extent. One aspect not depicted in this scheme is the fact that SNARE complexes function in a cooperative manner, with several complexes involved in fusing a
single synaptic vesicle with the plasmamembrane. Dominant-negative effects may emerge when mutations interfere with this cooperativity, as demonstrated for
an experimental mutation in SNAP25 (Mohrmann et al., 2010). Two types of genetic mechanisms fall somewhat outside this classification. (1) Gain-of-function
missense mutations are conceptually similar to functional or neomorph haploinsufficiency in heterozygous cases but, of course, cannot be considered a ‘‘weak’’
allele, as depicted here (example UNC13A P814L; Lipstein et al., 2017). Gain-of-function mutations can also be conceptually similar to recessive in homozygous
cases; i.e., these mutations are only symptomatic in homozygous cases (example STXBP1 L446F; Lammertse et al., 2020). (2) Proposed dominant-negative
cases are those where a mutant protein self-aggregates, also incorporating the normal protein, as proposed for STXBP1 (Guiberson et al., 2018); see discussion
in the main text. Finally, to our knowledge, several possible genetic mechanisms have not yet been reported for SNAREopathies; e.g., increased gene copy
number variants, variants that affect the gene promotor, mutations that affect the balance between splice variants, or cases where variation in more than a single
SNAREopathy gene in a single individual contributes to the pathogenesis.
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Reviewof energy from SNARE complex assembly (Rebane et al., 2018).
Missensemutations (G226R and V216E) in the SNARE domain of
syntaxin 1b have also been shown to change their interactome
(scenario 1c), especially the binding to MUNC18-1 and
MUNC13 (Vardar et al., 2020). The G226R mutation caused
impaired binding to MUNC18-1 but an increased affinity for
MUNC13 (scenario 1c) and also a reduced expression level (sce-
nario 1a). When expressed in STX1A/B-deficient neurons,
STX1BG226R produced a reduction in evoked post-synaptic cur-
rent (EPSC) amplitude because of a smaller RRP (Vardar et al.,
2020). The lower expression level did not seem to cause this
phenotype, and therefore it corresponds to scenarios 1b and
1c (Figure 3; Table 2).
Strikingly, for STXBP1 syndrome—the most frequent among
SNAREopathies (Table 1)—about 60% of mutations described
so far are truncations (nonsense, splice site, or frameshift) or par-
tial or whole gene deletions (Stamberger et al., 2016) expected to
reduce protein levels by 50%. This strongly suggests that insuf-
ficient expression is at the center of this disorder (scenario 1a).
This even extends to missense mutations, which are found scat-
tered throughout the gene without obvious clustering (Stam-
berger et al., 2016) and may impair protein stability and reduce28 Neuron 107, July 8, 2020protein levels by less than 50%. Seven missense mutations
showed different cellular phenotypes when expressed in
STXBP1 null neurons, with five mutants rescuing neuron viability
(Kovacevic et al., 2018) (which is compromised in STXBP1-null
neurons; see Other Aspects of SNARE Function; Heeroma
et al., 2004; Santos et al., 2017; Verhage et al., 2000). Expression
levels at the synapse were consistently reduced, and further
analysis of four mutants showed reduced protein stability.
Indeed, reduced protein stability of missense mutations has
been reported by several laboratories (Chai et al., 2016; Guiber-
son et al., 2018; Kovacevic et al., 2018; Martin et al., 2014; Saitsu
et al., 2010). It has also been reported that some missense mu-
tants, in addition to reduced stability, also form protein clusters
that might trap wild-type protein (Chai et al., 2016), resulting in
its degradation (Guiberson et al., 2018). This would imply a domi-
nant-negative scenario (scenario 2) (Guiberson et al., 2018).
Accordingly, expressing mutant protein on a wild-type back-
ground in C. elegans resulted in mild impairment of neurotrans-
mitter release (Guiberson et al., 2018). However, overexpression
of missense mutants in murine STXBP1 heterozygous neurons
did not affect neurotransmission (Kovacevic et al., 2018), and hu-
mans heterozygous for partial or complete STXBP1 deletions or
Table 2. Genetic Disease Mechanisms
Modes Main Mutation Types Therapeutic Strategies SNAREopathy Examples References
(1) Haploinsufficient a level haploinsufficiency: mutations
reduce protein and/or mRNA level
and stability; cellular protein level
below critical threshold. Function
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Shown are different molecular genetic diseasemechanisms relevant for SNAREopathies; see also Figure 3. Combinations of these situations are also plausible (and have been reported; e.g., 1a +



























Figure 4. Possible Microcircuit Defect in
SNAREopathies
We hypothesize that microcircuit failure, espe-
cially at high stimulation frequencies, might
explain pervasive clinical symptoms, such as ID
and seizures. Feedforward inhibition takes place
via an intercalated parvalbumin-positive basket
cell, whereas feedback inhibition occurs via acti-
vation of a somatostatin-positive Martinotti cell.
The defects in the microcircuit might either affect
GABAergic neurotransmission (1), glutamatergic
neurotransmission (2), or breakdown of temporal
summation or inhibition windows (3). Finally, se-
lective degeneration of a neuronal subtype (4)
might underlie disease, although this remains
unknown.
ll
Reviewtruncations show similar clinical phenotypes as heterozygotes of
missense mutations (Stamberger et al., 2016), whereas a domi-
nant mechanism commands that missense mutations are more
deleterious. Hence, the present data indicate a striking and so
far unexplained complexity where mutations in STXBP1 typically
lead to too low of an expression level (scenario 1a), whereas mu-
tations in the other proteins lead to impaired functionality (sce-
nario 1b/1c or 2), and only occasionally are expression levels
affected, as demonstrated for one SYT1 mutation (Baker et al.,
2018) and an insertion or deletion mutation in STX1B (Vardar et
al., 2020).
Occasionally a missensemutation leads to a protein with gain-
of-function characteristics; i.e., a gain-of-function neomorph
(scenario 1c). A UNC13A case (P814L) carries a gain-of-function
mutation (increased fusion probability), as indicated by experi-
ments in mouse neurons (Lipstein et al., 2017), but still causes
a motor disorder, mild ID, and autism. A gain-of-function homo-
zygous missense STXBP1 mutation (L446F) has been reported
recently in two siblings diagnosed with ID, epilepsy, and electro-
encephalogram (EEG) abnormalities (Lammertse et al., 2020).
Upon expression in STXBP1-null mouse neurons, evoked syn-
aptic transmission and the vesicular release probability were
increased 2-fold. The disease-causing V216E mutation in
STX1B is located next to a ‘‘furled loop’’ in MUNC18-1, which
regulates the autoinhibitory configuration of the STX1B-
MUNC18-1 complex (Vardar et al., 2020). The mutation causes
increased EPSC size and vesicular release probability. In all
three gain-of-function mutations, the RRP size was unchanged,
and the increased release probability was associated with
changes in short-term plasticity (increased depression). In spite30 Neuron 107, July 8, 2020of these striking cell-physiological simi-
larities, the clinical features of the pa-
tients were diverse. The STXBP1 L446F
patients had severe epilepsy (diagnosed
as Lennox-Gastaut syndrome; Lammer-
tse et al., 2020)), the UNC13A patient
was autistic and without known epilepsy
(Lipstein et al., 2017), and the
STX1B V216E patient had cognitive
impairment, macrocephaly, and ataxia
(Vardar et al., 2020). This underscores
the marked difference in clinical featuresin spite of mutations with seemingly similar cell-physiological
consequences.
Explaining Complexity I: Symptom Severity Generally
Scales with Genetic Redundancy
The remarkable complexity in symptoms and genetic mecha-
nisms among SNAREopathy cases suggests that additional ge-
netic and/or environmental factors contribute substantially to
disease expression. Therefore, it seems crucial to consider the
rest of the genome when studying individual cases and, e.g.,
study patient-own models. In addition, to start understanding
this striking complexity, at least two scenarios may be consid-
ered: (1) functional redundancy may differ between SNAREop-
athy cases, and (2) subtle differences may exist in how different
components of the SNARE fusion machine are rate-limiting in
different types of neurons.
Genetic redundancy, the principle that other genes compen-
sate partially or wholly for functionality loss of another gene, has
beenextensively studied for all SNAREopathy genes in nullmutant
(knockout [KO]) mice, which typically display perinatal lethality:
SNAP25 (Washbourne et al., 2002), STXBP1/MUNC18-1
(Verhage et al., 2000), VAMP2 (Schoch et al., 2001),UNC13A (Au-
gustin et al., 1999), STX1A (Wu et al., 2015), STX1A/B double KO
(Vardar et al., 2016), RIMS1/2 double KO (Schoch et al., 2006),
and CPLX1/2 double KO (Reim et al., 2001) (Table 1). Lethality
upon disruption of SNAREopathy genes extends to invertebrates
(Table 1 and references therein). This indicates that the protein
machinery of evoked neurotransmitter release displays very
limited redundancy. Although paralogs exist, they typically do
not perform in what matters most at the synapse: fast
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expression of exogenous SNAP23, the closest relative of
SNAP25, substitutes for SNAP25 in several functions, including
neuronal survival and fusion of DCVs, and even priming and spon-
taneous and slow (‘‘asynchronous’’) fusion of synaptic vesicles,
but SNAP23 does not support fast synchronized release (Arora
et al., 2017; Delgado-Martı́nez et al., 2007). Similarly, upon elimi-
nation of synaptotagmin-1 or -2 expression, which are dedicated
to fast synchronized release, the co-existenceof synaptotagmin-7
allows slow (‘‘asynchronous’’) release topersist (Bacaj et al., 2013;
Schonn et al., 2008) but at a level incompatible with life (Geppert
et al., 1994; Pang et al., 2006). Yet another example is that exog-
enous MUNC18-2 (or even the more distantly related MUNC18-3)
substitute for several cellular functions ofMUNC18-1KOneurons,
including cell viability, but, again, fast synchronized release is
almost eliminated because of destabilization of the primed vesicle
state (Gulyás-Kovács et al., 2007; He et al., 2017). Thus, although
the neuronal SNARE complex and its associated proteins perform
a function (membrane fusion) that is similar in other membrane
trafficking processes in the cell, the neuronal fusion apparatus is
so specialized and integrated that none of the paralogs can really
substitute. Thus, the major effect of single mutations in several
SNAREopathy genes is the price paid for extensive specialization
and optimization of fast synaptic transmission.
However, in the case of syntaxin-1, the paralogs STX1A and
STX1Bhavesimilar functionality in synaptic transmission, andmu-
tations in STX1B often cause comparatively mild symptoms:
febrile seizures and mild NDD and disability, which might be ex-
plained by partial redundancy with STX1A. Consistent with this,
currently noSTX1Amutations are described in relation to enceph-
alopathies (one reported case awaits causal evidence; Table 1).
The redundancy is evident from the fact that STX1A/B double
KO mice die in the embryonal state (Mishima et al., 2014; Vardar
et al., 2016),whereasSTX1BKOmicediewithin 2weeks (Mishima
et al., 2014; Wu et al., 2015), and STX1A KOmice are viable (Fuji-
wara et al., 2006; Gerber et al., 2008; Table 1). Consistent with the
idea that redundancy predicts severity, invertebrates that express
only one syntaxin-1 orthologdisplay early lethality upondisruption
of the gene (Saifee et al., 1998;Schulze et al., 1995; Table 1). In the
case of complexins, two paralogs support fast synaptic transmis-
sion:CPLX1 andCPLX2.CPLX1 deficiency inmice leads to death
within 4 months (Reim et al., 2001), whereas CPLX2 KO mice are
viable (Reim et al., 2001), but double-null mutants die immediately
after birth (Reim et al., 2001), again indicating redundancy. For
CPLX1, all patients identified so far are homozygous children
fromconsanguineous familiescarryingmissenseornonsensemu-
tations (Table 1), and the parents are described as asymptomatic
(Redler et al., 2017). Together with the lack of any known patients
with heterozygous mutations, this indicates that, for CPLX1, het-
erozygous mutations are tolerated, most likely because of partial
redundancywithCPLX2. Similarly, forUNC13AandRIMS1, genes
for which close paralogs exist that (partially) compensate for the
loss of the proteins in mice (see above), the symptoms in human
carriers with mutations in these genes are relatively mild (Table
1). Hence, redundancy helps to explain the fact that STX1B,
UNC13A, and RIMS1 cases are relatively mild and CPLX cases
are homozygous. Generally, disease severity scales with how
much redundancy is observed; e.g., in genetic studies of mice.Explaining Complexity II: Heterogeneous Effect in
Neuronal Networks
Although the overall clinical severity appears to correlate with
functional redundancy (versus the lack thereof), how SNAREop-
athy mutations lead to neurodevelopmental impairments re-
mains unexplained. Subtle differences in rate-limiting steps in
synaptic transmission in different neuronal subtypes, together
with the organization of brain micro-circuits, provide a starting
point to explain this. Among the main developmental symptoms,
seizures, intellectual disability, and autism spectrum disorder
(ASD) are common and have all been linked to dysregulation of
the excitation/inhibition (E/I) balance in brain circuits (Golden
et al., 2018). At first glance, the SNARE machinery appears to
be universally required in all synapses, glutamatergic (excitation)
and GABAergic (inhibition). Thus, the etiology of the disease
does not predict E/I dysregulation. However, glutamatergic
and GABAergic neurotransmission may display slightly different
susceptibilities to SNAREopathy gene mutations. For instance,
inhibitory synaptic transmission showed stronger rundown
than excitatory transmission during high-frequency train stimula-
tion in STXBP1+/ (haploinsufficient) neurons in vitro (Toonen
et al., 2006). Such a differential effect is expected to cause hy-
perexcitation during high-frequency bursting. In a recent study
of STXBP1 haploinsufficient mice, impaired inhibition was iden-
tified in cortical brain slices (Chen et al., 2020). The mechanisms
depended on the interneuron type. In parvalbumin-positive (bas-
ket) neurons (PV neurons), connectivity rates to pyramidal neu-
rons were normal, but the unitary connection strength was
reduced, whereas for somatostatin-positive (Martinotti) neurons,
the connectivity rates were reduced, but the unitary strength was
normal; for both interneuron types, short-term plasticity was un-
affected (Chen et al., 2020). Conversely, another study of
STXBP1+/ mice concluded that seizures in these mice are trig-
gered by a reduction in cortical excitatory neurotransmission to
fast-spiking interneurons in the striatum (Miyamoto et al.,
2019). In this case, STXBP1 haploinsufficiency would essentially
be a disease of cortical glutamatergic synapses, resulting in fail-
ure to recruit GABAergic interneurons. Given these observations
in mouse model neurons, it is plausible that altered (impaired)
SNAREopathy gene function affects different components in
neuronal networks in the brain to a different extent, creating an
imbalance. Such a scenario has also been proposed for channe-
lopathies where causative genes are also expressed in excit-
atory and inhibitory neurons, whereas mutations do cause syn-
dromic epilepsies (Staley, 2015).
A more specific explanation of SNAREopathy symptoms re-
quires a deeper understanding of the extent to which the
different components of mixed glutamatergic-GABAergic micro-
circuits in the brain are susceptible to SNAREopathy gene
mutations; e.g., feedforward and feedback inhibition circuits
(Figure 4). Feedforward circuits are found in the cortex, hippo-
campus, and striatum, among others. Because inhibition in-
volves two synapses in series (di-synaptic), whereas excitation
is monosynaptic, excitation of the circuit results in a brief time
window within which the principal cell can sum upmultiple excit-
atory inputs and elicit an action potential (Hu et al., 2014; Pouille
and Scanziani, 2001). A generalized synaptic impairment might
affect this circuit in multiple ways. It might disproportionallyNeuron 107, July 8, 2020 31
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possibility 1; Chen et al., 2020), or impaired excitatory transmis-
sion could impair recruitment of the PV interneuron (Figure 4,
possibility 2; Miyamoto et al., 2019). Breakdown of inhibition
should be considered not only in terms of its magnitude but
also in terms of its timing (Figure 4, possibility 3); a break-down
in synchronicity or inconsistent activation of interneurons could
potentially lead to prolonged or ill-defined summation windows.
We hypothesize that an impaired summation window might be
correlated with ID, which is a particularly consistent feature of
SNAREopathies (Figure 2; Table 1). For instance, allSTXBP1mu-
tation carriers are diagnosed with ID, whereas epilepsy is not
found in all patients (Stamberger et al., 2016). This kind of impair-
ment might fundamentally compromise the brain’s processing
ability, leading to ID. It could also cause defects in voluntary
movement, another computational-intensive activity, which is
consistently affected (Table 1). Initially, homeostatic mecha-
nisms might compensate for the impaired neurotransmitter
release anticipated for most mutations and normalize synaptic
transmission (Fernandes and Carvalho, 2016; Turrigiano, 2012;
Vitureira et al., 2012). However, at higher frequencies, presynap-
tic impairments will lead to microcircuit failure. Similar impair-
ments in synaptic homeostasis could be envisioned in feedback
inhibition circuits, which, in the cortex, typically involve somato-
statin-positive Martinotti cells (Silberberg and Markram, 2007;
Figure 4).
To better understand how SNAREopathy mutations affect the
stability of brain networks, it seems crucial to trace effects back
to their origin and establish how presynaptic impairments affect
early brain development (e.g., microcircuit and system connec-
tivity) and the timing of known maturation checkpoints, such as
the GABA/Cl switch and subunit switches in GABA and gluta-
mate receptors. Although SNAREopathy genes are not known
to have a prominent role in early development (see below), the
earliest, subtle effects certainly affect all subsequent stages of
brain development but happen long before carriers enter the
healthcare system, and it seems impossible to backtrack to
the initial dysregulation in the carriers themselves. Mouse
models with good construct and face validity may help to obtain
leads toward such early events.
Other Aspects of SNARE Function
Many studies emphasize the central role of the eight SNAREop-
athy genes in synaptic vesicle fusion and synaptic transmission,
but other biological functions have also been demonstrated for
these genes. Dysregulation of these functions because of
pathogenic mutations may also contribute to SNAREopathy
pathogenesis and potentially also to the diversity in clinical man-
ifestations because the contribution of these eight genes to other
processes might bemore diverse than for synaptic transmission.
First, SNAREopathy genes have been proposed to have a role
in axon outgrowth during brain development (Verhage et al.,
2000, and references therein; Hamada et al., 2017; Yamamoto
et al., 2019). Human mutation carriers show early symptoms,
consistent with dysregulation during initial brain development.
However, in vivo studies in null mutant mice for SNAREopathy
genes (see references in Table 1) indicate that the brain develops
normally, including correct targeting of the main nerve bundles32 Neuron 107, July 8, 2020and normal connectivity, in the absence of SNAREopathy
proteins. This suggests that SNAREopathy genes are not major
factors in establishing the initial neuronal networks in the brain
during early brain development.
Second, SNAREopathy genes are also crucial for regulated
secretion of neuropeptides and neuromodulators from dense
core vesicles (Arora et al., 2017; Farina et al., 2015; Persoon
et al., 2019; Shimojo et al., 2015; van de Bospoort et al., 2012;
van Keimpema et al., 2017). Neuromodulators are important fac-
tors in the adult brain but also during maturation of brain net-
works, consistent with the early symptoms observed in human
mutation carriers. Neuromodulator and neuropeptide secretion
is a distinct secretory pathway for which much less information
is available than for synaptic vesicle exocytosis. The first indica-
tions suggest that SNAREopathy genes operate in a similar
concerted manner as for synaptic vesicle exocytosis and that
dysregulation of this pathwaymaywell contribute to SNAREopa-
thies but may not provide direct explanations for symptom di-
versity.
Finally, three SNAREopathy genes, STXBP1/MUNC18-1, and
SNAP25, STX1A/B, but not the other five, are known to be
essential for neuronal survival (Santos et al., 2017). Mutant
mice or primary neurons in culture show massive neuronal cell
death in the absence of the encoded proteins (Arora et al.,
2017; Santos et al., 2017; Vardar et al., 2016; Verhage et al.,
2000). This essential role in neuronal survival and/or mainte-
nance is distinct from their established role in synaptic transmis-
sion because (1) expression of non-neuronal paralogs prevents
cell death but does not restore synaptic transmission (Santos
et al., 2017) and (2) other mutant mice and/or neurons that lack
synaptic transmission do not show cell death (Schoch et al.,
2001; Varoqueaux et al., 2002). Sparse inactivation of the
STXBP1 gene in mice shows that its role in neuronal survival/
maintenance is cell autonomous (Heeroma et al., 2004). Hence,
in addition to the predicted effect of SNAREopathy gene muta-
tions on synaptic transmission, effects on neuronal survival
and/or maintenance cannot be excluded, and SNAREopathies
might, in some cases, involve progressive loss of neuronal sub-
populations (Figure 4, possibility 4). However, so far, studies per-
formed in vitro failed to demonstrate a difference in neuronal sur-
vival for STXBP1 (Kovacevic et al., 2018; Patzke et al., 2015;
Verhage et al., 2000) or STX1B heterozygous neurons (Vardar
et al., 2016), indicating that neuronal survival is more robust to
mutations than synaptic transmission.
Conclusions and Perspective
Advances in clinical genetics have led to widespread genomic
testing of children with severe neurodevelopmental disorders
and an explosion of new clinicopathological connections. Pa-
tients with only partially overlapping clinical features and diverse
diagnoses have been found to share mutations in the core com-
ponents of the synaptic SNARE fusion machinery. Collectively
defining these cases, based on etiology and mechanism, as
SNAREopathies provides key advantages for a more systematic
analysis as a clinical subgroup with a common pathogenic start-
ing point to end the diagnostic odyssey for patient families, pro-
mote elucidation of common pathogenic pathways, and develop
intervention strategies. Mutations in SNAREopathy genes cause
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Reviewa strikingly diverse palette of symptoms, and the first mecha-
nistic studies demonstrate that the genetic and cell-physiolog-
ical disease mechanisms are also surprisingly diverse. Clinicians
and basic scientists must work together to find commonalities
among cases, at different stages of brain development and
different organizational levels in the brain (synapses, neurons,
networks, and brain systems), to understand how different clin-
ical manifestations emerge from a common pathogenic starting
point (mutations in a single, integrated molecular machine) and
to design rational intervention strategies. We argue that disease
severity generally scales with how much functional redundancy
is available for individual SNARE components and that subtle dif-
ferences in susceptibility to SNAREopathy mutations in different
components of neuronal networks provide a starting point for un-
derstanding neurodevelopmental manifestations. To achieve a
more complete understanding, we need to (1) systematically
analyze the links between the molecular disease mechanism
(as revealed in standardized in vitro systems) and dysregulation
at the level of the intact circuitry of the brain and (2) generate rele-
vant and diverse in vitro and in vivo disease models that better
recapitulate the diversity seen among affected humans. Given
the diversity in symptoms even among carriers of mutations in
a single SNAREopathy gene, it seems crucial to study patient-
own model systems (e.g., induced pluripotent stem cell [iPSC]-
derived human neurons; Fenske et al., 2019; Meijer et al.,
2019; Rhee et al., 2019) and (3) follow in vivo disease models
over longer time spans to assess the developmental and
possible neurodegenerative aspects of the diseases, which ac-
count for a part of patient variability. Finally, (4) clinical analyses
should focus on further expanding the detailed characterization
of developmental trajectories and symptomatology and explore
rational and symptomatic treatment improvement. Finally, the
implication of network-level E/I deregulation as a downstream
consequence of SNAREopathies may be tested by clinical mea-
sures of brain function, such as EEG. In any scenario, a clinical
developmental natural history study is indispensable to evaluate
the success of future therapies.
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